jueves, 12 de noviembre de 2026
Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT
https://na.eventscloud.com/website/98255/
In this 90-minute symposium, some of the foremost experts in light-chain (AL) amyloidosis research and care will share actionable strategies for navigating complex challenges in this rare disease.
Topics will include
Diagnosis, staging, and stratifying: Improving timeliness and accuracy
Treatment: Developing personalized, evidence-based plans
Patient support: Helping patients navigate the long journey
Workflows: Optimizing systems and teamwork
The event speakers, involved in some of the most consequential trials in AL amyloidosis, will also examine key data for current treatments and novel approaches like fibril targeting. Register now to secure your spot, and prepare your questions for the live Q&A at the end of the session.
Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition
Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT
https://na.eventscloud.com/website/98255/
This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia.
Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition
Viewpoint: ‘Sanitation and nutrition not vaccines’: The rejectionists’ latest false substitute for staying up to date on your shots Jess Steier | November 12, 2026
https://geneticliteracyproject.org/2026/11/12/viewpoint-sanitation-and-nutrition-not-vaccines-the-rejectionists-latest-false-substitute-for-staying-up-to-date-on-your-shots/
Has anyone ever heard matzoh ball soup referred to as Jewish penicillin? I’ve called it that my whole life. It was the first thing my mom made whenever I was sick, a pot chock full of veggies, herbs, and protein (and the matzoh balls!). It was good for my body and good for my soul, a warm generational hug in a bowl. Of course, we know soup isn’t actually penicillin, which is an antibiotic (and I was usually eating it for a cold or the flu, which are caused by viruses that antibiotics can’t treat anyway). That soup nourished me and comforted me while my body fought off whatever I had, but it couldn’t keep me from catching the next bug going around school.
Clonal haematopoiesis: a major link in the cancer–Alzheimer's disease inverse correlation eBioMedicine (+...)
Clonal haematopoiesis: a major link in the cancer–Alzheimer's disease inverse correlation
eBioMedicine
https://www.thelancet.com/journals/ebiom/issue/vol133nonull/PIIS2352-3964(26)X2009-6
First characterised in 2014, clonal haematopoiesis is a condition defined by the expansion of a haematopoietic stem cell clone, and its progeny, carrying somatic mutations in leukaemia-associated genes. Sensitive sequencing techniques show that clonal haematopoiesis, irrespective of clone size, becomes near-universal with ageing. A related term, clonal haematopoiesis of indeterminate potential (CHIP), describes the presence of a clone that has expanded to a variant allele fraction of ≥2% (and as a result ≥4% of nucleated blood cells) and is considered clinically significant. As expected, CHIP is a strong risk factor for subsequent haematologic cancers (hazard ratio 12·9 [95% CI 5·8–28·7]). Incident coronary heart disease (2·0 [1·2–3·4]), ischaemic stroke (2·6 [1·4–4·8]), and all-cause mortality (1·4 [1·1–1·8]) also increased. Mechanistic studies in animal models suggest that altered gene expression and changes in the function of circulating mutant macrophages are likely to contribute to the more rapid expansion of atherosclerotic lesions in the presence of CHIP.
Move over BMI: new obesity definition is better for predicting your health A fresh approach considers waist circumference, rather than just weight and height, providing a more accurate classification. By Mariana Lenharo
Move over BMI: new obesity definition is better for predicting your health
A fresh approach considers waist circumference, rather than just weight and height, providing a more accurate classification.
By Mariana Lenharo
https://www.nature.com/articles/d41586-026-03636-5
Clinicians have debated for years whether body mass index (BMI) — a metric derived from a person’s height and weight — is the best way to define and diagnose obesity. Now, an approach that measures waist circumference and focuses more closely on excess body fat has proved to be better than BMI at predicting a person’s risk of death.
RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus Vaccines and monoclonal antibody injections are cutting hospitalizations for the respiratory virus. By Liam Drew
RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus
Vaccines and monoclonal antibody injections are cutting hospitalizations for the respiratory virus.
By Liam Drew
https://www.nature.com/articles/d41586-026-03573-3
“Something’s wrong with the data. There are too few people in hospitals” with respiratory syncytial virus (RSV), epidemiologist Caroline Klint Johannesen recalls a colleague remarking while analysing Danish health records for last winter.
New culprit in early Alzheimer’s: Blood–brain barrier blocks protective proteins The brain relies on crucial proteins to maintain neurons. This system is disrupted in mice with neurological disease. By Mohana Basu
New culprit in early Alzheimer’s: Blood–brain barrier blocks protective proteins
The brain relies on crucial proteins to maintain neurons. This system is disrupted in mice with neurological disease.
By Mohana Basu
For decades, scientists thought of the blood–brain barrier as an impenetrable layer. Overtime that view has changed, as researchers realized the barrier was more permeable than first thought. Now a team have catalogued almost 100 proteins that can pass through it to maintain brain health.1
https://www.nature.com/articles/d41586-026-03655-2?utm_source=Live+Audience&utm_campaign=21e610d5d7-nature-briefing-daily-20261111&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Brain-protein highway clogs in Alzheimer’s
Researchers have catalogued almost 100 proteins that get a free pass through the blood–brain barrier to maintain the health of neurons. Most of these proteins were produced in distant organs, particularly the liver. The team found that the transport of some of these proteins is disrupted in mice with a brain disease that mimics early-stage Alzheimer’s disease. The work suggests that the brain actively imports the proteins it needs to stay healthy, and that the breakdown of that transport drives the dysfunction seen in neurodegenerative disease, says neuroscientist and study co-author Andrew Yang.
Why We Need to End the 'Overall Survival Obsession' (+++++)
Why We Need to End the 'Overall Survival Obsession'
https://www.medscape.com/viewarticle/why-we-need-end-overall-survival-obsession-2026a10014gx?ecd=wnl_edit_tpal_etid8893653&uac=148436CN&impID=8893653
Tau Accumulates More Than Twice as Fast in Early-Onset AD
https://www.medscape.com/viewarticle/tau-accumulates-more-than-twice-fast-early-onset-ad-2026a100170o?ecd=wnl_edit_tpal_etid8893653&uac=148436CN&impID=8893653
Fast Five Quiz: Identify and Treat Crohn's Disease
https://reference.medscape.com/viewarticle/fast-five-quiz-identify-and-treat-crohns-disease-2025a1000ec7?ecd=wnl_edit_tpal_etid8893653&uac=148436CN&impID=8893653
Is the Rectal Exam Useful in Cauda Equina Syndrome?
https://www.medscape.com/viewarticle/rectal-exam-useful-cauda-equina-syndrome-2026a10016ky?ecd=wnl_edit_tpal_etid8893653&uac=148436CN&impID=8893653
Psychiatrists Are Losing Autonomy. How Can We Reclaim It?
https://www.medscape.com/viewarticle/psychiatrists-are-losing-autonomy-how-can-we-reclaim-it-2026a100164o?ecd=wnl_edit_tpal_etid8893653&uac=148436CN&impID=8893653
Oncology News: Can Chronic Stress Influence Cancer Progression? (+...) (+...) (+...) (+...)
Oncology News
Can Chronic Stress Influence Cancer Progression?
Stress-related hormonal and immune signals may interact with tumor biology, but current evidence does not establish that psychological stress causes cancer progression.
Medscape News Europe, November 12, 2026
https://www.medscape.com/index/list_13474_0
Oncology Perspective
Why We Need to End the 'Overall Survival Obsession'
Waiting for OS delays vital care. Dr Mark Kris explains why prioritizing progression-free survival is both better medicine and faster drug development.
Medscape Oncology, November 10, 2026
https://www.medscape.com/index/list_13293_0
Oncology Conferences
ESMO 2026
Read clinically focused news coverage of key developments from ESMO 2026.
Medscape Oncology, October 23, 2026
https://www.medscape.com/index/list_339_0
Oncology Cases & Quizzes
Quiz: Recognizing and Diagnosing CLL
Can you recognize typical CLL findings and interpret its diagnostic and staging features? Test your knowledge with five questions.
Medscape Reference, November 11, 2026
https://www.medscape.com/index/list_12039_0
FDA Approves Pimicotinib for Symptomatic TGCT
https://www.medscape.com/viewarticle/fda-approves-pimicotinib-symptomatic-tgct-2026a10016zp?ecd=WNL_trdalrt_pos1_ous_261112_etid8894264&uac=148436CN&impID=8894264
The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating patients with symptomatic tenosynovial giant cell tumors (TGCTs) for which surgical resection will potentially cause worsening functional limitations or severe morbidity.
Pimicotinib, a CSF-1R TKI, joins two others already on the US market for the indication: vimseltinib and pexidartinib.
Medscape Congenital Heart Disease Yasmine S. Ali, MD, MSci
https://reference.medscape.com/p11/congenital-heart-disease-2026a100128d?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
Tetralogy of Fallot consists, as the name suggests, of four structural congenital heart defects: a malalignment ventricular septal defect, right ventricular outflow tract obstruction (also known as subpulmonic stenosis), an overriding aorta, and RV hypertrophy, all consequences of anterocephalad deviation of the outlet septum. It is the most common cyanotic congenital heart lesion, with a birth prevalence of 3-5 per 10,000 live births, and roughly 20% of cases occur with a genetic syndrome, most commonly 22q11.2 deletion syndrome.[1,2] Because most patients now survive childhood repair, tetralogy of Fallot in adults is defined less by the original anatomy than by the aftereffects of treatment: Chronic pulmonary regurgitation is nearly universal after transannular patch repair and drives progressive RV dilation, exercise intolerance, arrhythmia, and sudden cardiac death. Surveillance includes serial cardiac MRI, exercise testing, and rhythm monitoring, with surgical or transcatheter pulmonary valve replacement timed to preempt irreversible RV dysfunction.
Diagnosis and Treatment of Cervical Cancer Sarah A. Ackroyd, MD, MPH
https://reference.medscape.com/p11/diagnosis-and-treatment-cervical-cancer-2026a10013lq?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
Cervical cancer is the fourth most common cancer among women worldwide and is the 22nd most common cancer in the United States, representing 0.6% of new cancer cases and 0.7% of deaths nationally. In the US in 2026, there were an estimated 13,490 new cases and 4200 deaths. Cervical cancer also affects younger women; it's the second-leading cause of cancer death in those aged 20-39 years and the fourth-leading cause of cancer death for those aged 40-49 years.[1]
Physical Symptoms of Stress Nameera Temkar, MD
https://reference.medscape.com/p11/physical-symptoms-stress-2026a100128e?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
Chronic physical and/or psychological stress are well known to have a deleterious effect on mental health. Physiologic stress responses can also lead to a host of physical symptoms affecting virtually every organ system in the body.
Diagnosis and Management of Hypertension in Primary Care Source: Department of Veterans Affairs, Department of Defense
https://reference.medscape.com/cc2/p10/diagnose-manage-hypertension-primary-care-va-dod-guideline-2026a10015ud?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
Elevated BP is an established risk factor for conditions like CAD, HF, stroke, peripheral vascular disease, CKD, and cognitive decline, and conditions such as CKD and/or diabetes can elevate hypertensive risk. Hypertension, or pathologically elevated BP, is a silent asymptomatic condition, which is considered a modifiable risk factor for CVD. BP progressively increases with advancing age, and the prevalence of hypertension varies by age, sex, and ethnicity.
In 2026, VA/DOD published an update to its clinical guideline on hypertension; this Medscape summary of the guideline covers diagnosis, monitoring, and...
Diagnosis, Treatment, and Monitoring of Long-Chain Fatty Acid Oxidation Disorders Source: International Consensus Group
https://reference.medscape.com/cc2/p10/long-chain-fatty-acid-oxidation-lc-faod-guidelines-2026a10014ez?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
This Medscape guideline summary includes recommendations from an international consensus guideline on LC-FAODs, a series of inherited defects of mitochondrial β-oxidation that impair energy generation during fasting or metabolic stress. The LC-FAODs addressed in this guideline are CPT1a deficiency, CACT deficiency, CPT2 deficiency, VLCAD deficiency, LCHAD deficiency, and TFP/MTP deficiency. For further information, including grading of recommendations and discussions of the evidence base, refer to the full guideline.
Evaluation, Diagnosis, and Management of Headache Source: Department of Veterans Affairs, Department of Defense; Medically Reviewed by Dr Yasmine Ali
https://reference.medscape.com/cc2/p10/va-dod-headache-guideline-2026a100125n?ecd=mkm_ret_261112_mscpmrk-OUS_DisReferences_etid8886540&uac=148436CN&impID=8886540
The 2023 VA/DoD guideline provides recommendations on the evaluation and management of headache. This Medscape guideline summary covers initial evaluation, differentiation of primary and secondary headache, diagnostic criteria for TTH, migraine, and cluster headache, three secondary headache types (cervicogenic headache, PTH, and MOH), and treatment with medications, procedures, neuromodulation, and nonpharmacologic approaches.
miércoles, 11 de noviembre de 2026
A Man on Ibrutinib Develops Cerebral Aspergillosis Wolfgang Paik
https://www.medscape.com/viewarticle/man-ibrutinib-develops-cerebral-aspergillosis-2026a100173i?src=
Cerebral aspergillosis can present without fever or systemic inflammation in patients receiving targeted hematologic therapies, with subtle cognitive, language, and gait deficits that may mimic those of stroke or encephalopathy. Although neuroimaging can identify multifocal enhancing lesions with extensive edema, it may not distinguish fungal, bacterial, or neoplastic diseases. Therefore, histopathologic examination of resected tissue may be necessary to establish a diagnosis.
Oncology News: Q&A: The Long Shadow of Financial Toxicity in Cancer Care (+...)
Oncology News
Q&A: The Long Shadow of Financial Toxicity in Cancer Care
As care costs continue to rise, financial toxicity is a key barrier to equitable cancer treatment.
Medscape Medical News, November 11, 2026
https://www.medscape.com/index/list_13474_0
Uncertainty reduction as a candidate primary reinforcer: an evolutionary and neural account Alan Lincoln1,* (++...)
https://www.academia.edu/3071-4087/2/3/10.20935/AcadNeurosci8451
This integrative review proposes that the reduction in uncertainty may function as a candidate primary reinforcer in humans. The proposed mechanism is positive prediction error coding by the mesolimbic dopamine system within nucleus accumbens and lateral habenula (NAc-LHb) opponent-process circuitry, gated and refined by later cerebellar and cortical additions. Because the dopaminergic signal responds to prediction resolution rather than to what is predicted, certainty operates as a reinforcer across sensory, motor, social, and propositional domains. The case is developed through three converging arguments: functional, mechanistic, and phylogenetic. The review first documents the conservation of NAc-LHb prediction error circuitry from lampreys to mammals and the matching law as a quantitative description of behavioral allocation. It then traces cerebellar emergence, forward modeling, and an ultrafast disynaptic cerebellum-to-NAc pathway that modulates reward valuation before cortical evaluation completes. It further traces cortical evolution into executive and language-supporting structures, integrating recent causal and human electroencephalogram (EEG) evidence for hierarchical cortical predictive coding as a layer above subcortical and cerebellar contributions. Finally, it addresses system integration and articulates a synthesis between free energy minimization and behavior-analytic motivating operations, proposing that motivating operations are the behavioral implementation of free energy gradients across domains, such that the list of primary reinforcers is principled rather than arbitrary. A falsifiable empirical test is proposed: pairing an arbitrary neutral cue with the resolution of a probabilistic prediction should produce conditioning curves quantitatively similar to those produced by pairing with food or water. On balance, uncertainty reduction is not yet established as a primary reinforcer in the same sense as food or water, but it is a strong candidate for a trans-domain motivational process that can recruit reward, aversion, precision-weighting, and belief-updating systems. Implications are noted for healthy belief revision, neurodevelopmental and psychiatric conditions, and contemporary digital information environments.
https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav
Read our latest HIV Drug Therapy Glasgow 2026 content (++++)
Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study
Free with registration until Nov 19, 2026
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00148-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz--GKBEzW8lbKNdxpPqI3pLeNWKucj7cfs9rrHPxONZYYipZcycdPbdpQC2qCdHv8nH8oG36OIqH6rhP8CZToUcfg0ZOyQ&_hsmi=448348523&utm_content=448348523&utm_source=hs_email
Long-acting antibody-based regimens might reduce treatment burden for people living with HIV. We aimed to assess safety, pharmacokinetics, and antiviral activity of TMB-365, a CD4-directed monoclonal antibody, combined with TMB-380, a long-acting broadly neutralising monoclonal antibody targeting gp120 CD4-binding site.
SERIES
Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV
Free with registration
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00231-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz--yfNAKU-pLsQjfGwTnoYaQ53Mz54ssmVs7-6G_O2JIE1vVE_57j1QwA2pci1z62nbbifPicWyTl9O994a387m1oI8k7A&_hsmi=448348523&utm_content=448348523&utm_source=hs_email
Return to health accounts for only part of the weight gain observed with modern antiretroviral therapy (ART). A fuller account requires integrating recovery from HIV-related catabolism, HIV-associated adipose tissue remodelling, withdrawal of weight-suppressive antiretrovirals, possible direct or permissive effects of newer agents, individual susceptibility, and obesogenic environments. Evidence from ART initiation and switch studies, PrEP trials, and mechanistic research in adipose tissue suggests that ART-associated weight gain is heterogeneous rather than a uniform restorative process. Once adiposity is established, ART switching has a limited ability to reverse weight gain, consistent with the biological persistence of acquired adiposity. Future care should move beyond ART manipulation alone and incorporate early monitoring, body-composition assessment, cardiometabolic prevention, lifestyle intervention, and appropriate antiobesity pharmacotherapy
Weight management in people with HIV
Free with registration
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00229-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz-9HqHYdYVF_MAU9He7oy9aRFg67fN32jhDx8FpGlcBgNlQqY_vhTH137Vb7Dp-WmS5nVvX5jq-LIK9c5ApW5Hdzg8lYLA&_hsmi=448348523&utm_content=448348523&utm_source=hs_email
Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular–kidney–metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority. Behavioural interventions can be offered to improve diet and increase physical activity, including increasing protein intake and promoting regular physical activity. Additionally, there is a growing body of evidence to support the use of GLP-1 receptor agonist therapies in people with HIV, along with a historical literature showing the efficacy of tesamorelin; however, there are sparse data to direct the use of other approved obesity management medicines specific to this population. Finally, bariatric surgical interventions are suggested to be safe and efficacious for those with chronic HIV infection and comorbid obesity. This Series paper identifies a range of key evidence gaps and research priorities for obesity management in people with HIV, including a lack of trials of GLP-1 therapies in people with HIV powered to key clinical outcomes, such as major adverse cardiovascular events and body composition endpoints, implementation science to define models of care, and research on the heterogeneities in clinical outcomes of obesity treatment by sex.
HIV, obesity, and stigma: lessons for programmes, policy, and practice
Free with registration
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00236-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz-9d2FIceyi85rQ_VlEiwXkm1pfOBq5ZMAY-DoOHirb9WoWzNPKJwXe_kcw8UtjPOC5QP00LrD57n9Ni6ivqkbxpO0ihQg&_hsmi=448348523&utm_content=448348523&utm_source=hs_email
HIV has generated four decades of activism, research, and policy reform that produced measurement tools, theoretical frameworks, and consensus that stigma undermines prevention, delays treatment, and entrenches inequity. Weight stigma follows a strikingly similar pattern, operating through visibility, assumptions of personal control, and moralised concern, and is now recognised as a public health priority in its own right. These two forms of stigma increasingly intersect in the same bodies: antiretroviral therapy, particularly newer regimens, is associated with substantial weight gain, so that people once stigmatised for wasting now risk a second, contradictory stigma for excess weight. This intersection is complex; internalised stigma from either condition can resurface long after apparent resolution, even when viral suppression has been reached or after major weight loss. HIV and obesity differ in diagnostic certainty, visibility, permanence, and the origins of activism and legal protection, which helps explain why HIV stigma reduction remains decades ahead. Applying the Health Stigma and Discrimination Framework to this intersection clarifies shared drivers, facilitators, manifestations, and outcomes. Community leadership, rejection of false prevention-versus-treatment trade-offs, equitable access to pharmacotherapy, and integration of obesity care into existing HIV services offer a practical path towards reducing both stigmas.
FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.”
Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis by Chad Birt| Published on: Nov 10, 2026
Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis
by Chad Birt| Published on: Nov 10, 2026
Johan Maertens, MD, PhD, Professor of Hematology at University Hospitals Leuven (UZ Leuven) in Belgium and Principal Investigator of the OASIS study, discusses positive phase 3 trial results evaluating oral olorofim in patients with invasive aspergillosis.
https://checkrare.com/phase-3-oasis-study-shows-promise-of-oral-olorofim-for-invasive-aspergillosis/
Myasthenia Gravis by CheckRare Staff| Updated on: Nov 10, 2026
https://checkrare.com/myasthenia-gravis/
Myasthenia gravis (MG) is a chronic autoimmune disease that disrupts communication between nerves and muscles, causing fluctuating weakness that often worsens with activity. It can affect the muscles controlling the eyes, face, speech, swallowing, limbs, and breathing. Although MG can be serious and sometimes life-threatening, treatments can improve muscle function, control autoimmune activity, and help many patients achieve some symptom control. [1–4]
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF by Chad Birt| Published on: Nov 11, 2026
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF
by Chad Birt| Published on: Nov 11, 2026
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).
Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients.
https://checkrare.com/inhaled-treprostinil-reduces-multiple-disease-progression-events-in-ipf/
Highlights from The Liver Meeting 2026 | The CheckRare Brief by CheckRare Staff| Published on: Nov 11, 2026
Highlights from The Liver Meeting 2026 | The CheckRare Brief
by CheckRare Staff| Published on: Nov 11, 2026
In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.
https://checkrare.com/highlights-from-the-liver-meeting-2026-the-checkrare-brief/
NIST Is Turning Scientific Waste Into Cancer-Fighting Material November 10, 2026 By: Manny Mejias (++)
https://www.nist.gov/blogs/taking-measure/nist-turning-scientific-waste-cancer-fighting-material
Science and medicine are constantly evolving. So, research facilities sometimes end up with outdated materials that researchers no longer need.
In years past, cancer patients were treated with a type of radiation that doctors don’t use anymore.
But what happens to those old radioactive materials?
My Research Is Working Toward a Pain-Free Mammogram Alternative
May 20, 2026
https://www.nist.gov/blogs/taking-measure/my-research-working-toward-pain-free-mammogram-alternative
This NIST researcher aims to create a viable alternative to mammograms that is pain-free, highly accurate and can save even more lives than mammograms currently do.
The Gender Gap in Healthcare Assaults in Spain (+++ +++ +)
Avoid the Arm on the Same Side as Breast Cancer Surgery?
https://www.medscape.com/viewarticle/avoid-arm-same-side-breast-cancer-surgery-2026a10015xc?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
A 49-year-old woman with a history of right-sided breast cancer comes into the clinic for evaluation (after lumpectomy, lymph node dissection, and radiation). She is sent to the lab for blood work. The lab tech tries three times to draw blood from the left arm and is unsuccessful. Is it OK to draw blood from the right arm?
Sufficient Vitamin D Linked to Better Breast Cancer Survival
https://www.medscape.com/viewarticle/sufficient-vitamin-d-linked-better-breast-cancer-survival-2026a1001462?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
Hello. I'm Dr Maurie Markman, from City of Hope. I would like to discuss a very interesting, and I'm sure also controversial, paper and topic. The paper is entitled "Clinically Sufficient Vitamin D Levels With Survival and Cardiovascular Outcomes in a Prospective Cohort of 3,995 Individuals Diagnosed With Invasive Breast Cancer." This manuscript was published in the Journal of the National Comprehensive Cancer Network. }
Robotic Assistance Boosts Safety in Lung Biopsy
https://www.medscape.com/viewarticle/robotic-assistance-boosts-safety-lung-biopsy-2026a10016rz?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
Shape-sensing robotic-assisted bronchoscopy (ssRAB) was associated with significantly fewer complications than CT-guided transthoracic biopsy (CTTB), based on data presented at the Annual Conference of the American Association for Bronchology and Interventional Pulmonology.
Prescribing GLP-1s? Don't Overlook These Medication Adjustments
https://www.medscape.com/viewarticle/prescribing-glp-1s-dont-overlook-these-medication-2026a10015wy?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
GLP-1-based therapies have transformed the treatment of obesity and type 2 diabetes, with additional indications for cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities. As more patients start these medications, clinicians need to consider how treatment may affect patients’ existing medication regimens.
Multiple Sclerosis Treatment Choices: Expert Tips for the Generalist
https://www.medscape.com/viewarticle/multiple-sclerosis-treatment-choices-expert-tips-generalist-2026a10014z5?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
The Gender Gap in Healthcare Assaults in Spain
https://www.medscape.com/viewarticle/gender-gap-healthcare-assaults-spain-2026a10016s1?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
Women made up 80% of healthcare professionals who reported being assaulted in Spain’s National Health System (SNS) in 2025, according to an annual report. The report recorded 14,810 incidents involving women and 3753 involving men. The figures should be considered in light of the workforce: Women account for 76% of SNS healthcare professionals. Among those accused of the assaults, 57% were men and 43% were women.
Reported Penicillin Allergy Linked to Delayed Syphilis Treatment in Pregnancy
https://www.medscape.com/viewarticle/reported-penicillin-allergy-linked-delayed-syphilis-2026a10016pr?ecd=wnl_edit_tpal_etid8889470&uac=148436CN&impID=8889470
WASHINGTON, DC — It took nearly three times longer for pregnant patients with a reported penicillin allergy to receive appropriate treatment for syphilis compared to those without a reported penicillin allergy, according to findings from a retrospective cohort study presented at IDWeek in Washington, DC, October 23.
What will it take to integrate quantum computing into drug discovery? Quantum computing could help tackle some of drug discovery’s most difficult calculations. But better hardware, hybrid workflows, and closer collaboration with pharma will be needed to turn that potential into practical applications. Written byBree Foster, PhD
What will it take to integrate quantum computing into drug discovery?
Quantum computing could help tackle some of drug discovery’s most difficult calculations. But better hardware, hybrid workflows, and closer collaboration with pharma will be needed to turn that potential into practical applications.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/what-will-it-take-to-integrate-quantum-computing-into-drug-discovery-17643
Quantum computing is often discussed alongside AI as another technology that could accelerate drug discovery. But while AI uses patterns in data to generate predictions and hypotheses, quantum computing takes a fundamentally different approach to processing information.
While classical computing relies on conventional bits, which represent information as either a zero or a one, quantum computers use quantum bits, or qubits, which can exist in multiple states at once. This makes them potentially well suited to simulating the behavior of electrons and their interactions – processes that underpin chemical reactions and molecular properties but can be challenging to capture using classical computational methods.
Why four companies are chasing the same immune chokepoint No VAV1 drug has reached approval, and four are now in development. Insilico’s AI-designed degrader makes its case on where the molecule does not go. Written byAndrea Corona
Why four companies are chasing the same immune chokepoint
No VAV1 drug has reached approval, and four are now in development. Insilico’s AI-designed degrader makes its case on where the molecule does not go.
Written byAndrea Corona
https://www.drugdiscoverynews.com/why-four-companies-are-chasing-the-same-immune-chokepoint-17645
The protein at the center of one of immunology’s most crowded new races was considered undruggable until a few years ago.
VAV1, a guanine nucleotide exchange factor expressed almost exclusively in immune cells, relays signals from the T-cell and B-cell receptors into activation, proliferation, cytoskeletal remodeling, and cytokine release. “VAV1 sits at a choke point of adaptive immunity,” said Alex Zhavoronkov, founder and co-CEO of Insilico Medicine, the generative AI drug discovery company that nominated an oral VAV1 degrader as a preclinical candidate on October 13th. Because expression is restricted to immune cells, removing the protein could dampen pathogenic lymphocyte activity across several autoimmune diseases while sparing most other tissues.
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
https://www.fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-tenosynovial-giant-cell-tumor?utm_medium=email&utm_source=govdelivery
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity.
martes, 10 de noviembre de 2026
Late night eating and sleep habits damage gut health, increase metabolic disease risk
https://www.news-medical.net/news/20261109/Late-night-eating-and-sleep-habits-damage-gut-health-increase-metabolic-disease-risk.aspx
A new study led by UTHealth Houston identified a link between late-night eating and sleeping habits, gut health, and metabolic disease, offering new insights into why some individuals with obesity may face risk of inflammation and related health problems.
The findings were published in iScience and led by Faraz Bishehsari, MD, PhD, professor and director of the Gastroenterology Research Center in the Department of Internal Medicine at McGovern Medical School at UTHealth Houston
Most eligible teens miss out on advanced obesity treatments
https://www.news-medical.net/news/20261109/Most-eligible-teens-miss-out-on-advanced-obesity-treatments.aspx
Despite the arrival of powerful new anti-obesity medications and growing evidence supporting weight-loss surgery for adolescents, the vast majority of eligible teens are receiving neither treatment, according to a new study from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Pediatrics.
A child's sex may change how early sugar intake relates to body fat
https://www.news-medical.net/news/20261109/A-childs-sex-may-change-how-early-sugar-intake-relates-to-body-fat.aspx
Could the timing of sugar exposure matter as much as the amount consumed? Researchers examined diets from pregnancy through toddlerhood to investigate how early nutrition relates to children's developing body composition.
In a recent longitudinal study published on the medRxiv preprint* server, researchers evaluated whether a child's sex modified associations between early dietary sugar exposure and body composition. The investigators analyzed dietary and body-composition data from 130 mother-child dyads across the first 1,000 days (from conception to approximately 24 months) to examine how added sugars and fructose intake during pregnancy and early childhood related to body fat at two years.
Your Instagram photos may reveal more about loneliness than you think
https://www.news-medical.net/news/20261109/Your-Instagram-photos-may-reveal-more-about-loneliness-than-you-think.aspx
From late-night posts to facial expressions in profile pictures, researchers examined whether everyday Instagram habits could offer a window into an often-hidden aspect of mental health.
Research suggests that loneliness is associated with an increased risk of early death comparable to that associated with smoking. In a recent study published in the journal npj Mental Health Research, scientists at the University of California, San Diego, La Jolla, CA, USA, tested whether Instagram behavior among American college students reveals several distinct forms of loneliness.
Drinking 2–3 cups of coffee a day? A study of 495,000 adults links it to lower AF risk
https://www.news-medical.net/news/20261109/Drinking-2e280933-cups-of-coffee-a-day-A-study-of-495000-adults-links-it-to-lower-AF-risk.aspx
Could your daily coffee or tea habit influence your heart rhythm? A 13-year study involving nearly half a million UK adults examines how different consumption levels relate to atrial fibrillation risk, raising fresh questions about two of the world's most popular beverages.
In a recent study published in the journal Food & Nutrition Research, researchers investigated associations between tea and coffee intake and the risk of atrial fibrillation (AF). The findings linked coffee consumption to a modestly lower AF risk, particularly at 2–3 cups daily, while tea results were less consistent.
Why are some patients lying to their doctors to get antibiotics?
https://www.news-medical.net/news/20261110/Why-are-some-patients-lying-to-their-doctors-to-get-antibiotics.aspx
From feeling ignored by doctors to believing antibiotics are the only answer, new research reveals why some patients bend the truth to get prescriptions, and what this could mean for antibiotic resistance.
A recent study in the journal JAMA Network Open reports that in a survey of US adults, nearly 28% said they had at some point misrepresented their symptoms to clinicians to obtain antibiotics. Lower awareness of antibiotic risks and the dangers of antimicrobial resistance were associated with higher odds of such misrepresentation.
Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
https://www.news-medical.net/news/20261110/Qureighte28099s-fibrosis-imaging-biomarker-selected-by-Contineum-Therapeutics-as-a-secondary-endpoint-in-Phase-2-PROPEL-IPF-clinical-trial.aspx
Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.
Could Ozempic and Wegovy affect unborn babies?
https://www.news-medical.net/news/20261110/Could-Ozempic-and-Wegovy-affect-unborn-babies.aspx
They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds. But while medications such as Ozempic and Wegovy may also improve women’s chances of falling pregnant, what happens to their unborn babies if they continue to take the drugs during pregnancy?
Could a common diabetes drug help prevent long COVID?
https://www.news-medical.net/news/20261110/Could-a-common-diabetes-drug-help-prevent-long-COVID.aspx
A nationwide study suggests that prescribing the widely used diabetes drug metformin soon after COVID-19 infection may substantially reduce the risk of long COVID or death, reinforcing earlier clinical trial findings.
Prescription of metformin within six days of documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a 53% lower risk of developing long COVID or death over six months, according to a new study published in the Journal of Medical Virology.
Does Eating a Wider Variety of Plants Improve Your Health?
https://www.news-medical.net/health/Does-Eating-a-Wider-Variety-of-Plants-Improve-Your-Health.aspx
Could the number of plant species on your plate reveal something that portion sizes and food groups miss?
For decades, dietary advice has focused on consuming specific quantities of each food group. More recently, researchers are exploring whether species diversity itself acts as an independent marker of diet quality.
This concept, also known as dietary or food biodiversity, includes the diversity of plant and animal species consumed. Plant-focused approaches encourage consuming a wide range of fruits, vegetables, legumes, whole grains, nuts, seeds, herbs, and spices.2,4 Evidence links greater dietary species richness with better nutrient adequacy, while the independent health benefits of increasing plant species counts remain uncertain.1,4
Protein Leverage Hypothesis: Why Low-Protein Diets May Increase Calorie Intake
https://www.news-medical.net/health/Protein-Leverage-Hypothesis-Why-Low-Protein-Diets-May-Increase-Calorie-Intake.aspx
Can the protein proportion in a meal influence how much we eat? Researchers are examining the biological signals and dietary factors that shape hunger and fullness.
Modern food environments can create a mismatch between protein regulation and diets rich in non-protein energy. The protein leverage hypothesis proposes that this interaction may contribute to excessive energy intake and obesity, alongside other dietary and environmental influences.1
Purslane Health Benefits: Nutrition, Omega-3s, and Safety
https://www.news-medical.net/health/Purslane-Health-Benefits-Nutrition-Omega-3s-and-Safety.aspx
Often called a garden weed, purslane raises scientific questions about how its fatty acids, antioxidant compounds, and harvesting conditions affect its dietary value.
Introduction: From Common Weed to Powerhouse Greens
Purslane (Portulaca oleracea) is a nutrient-dense succulent widely consumed as a potherb in Central Europe, Asia, and the Mediterranean region. Historically, purslane has also been used to treat various inflammatory, gastrointestinal, respiratory, and skin conditions.1,2
New California law will restrict sales of some muscle-building supplements to minors (+... +)
https://www.foxnews.com/health
New California law will restrict sales of some muscle-building supplements to minors
Legislation covers over-the-counter diet pills and weight-loss dietary supplements, taking effect Jan 1
Melissa Rudy By Melissa Rudy Fox News
Published November 9, 2026 3:43pm EST
https://www.foxnews.com/health/california-law-restrict-sales-muscle-building-supplements-minors
Popular cooking methods may destroy key health benefits of top vegetable, experts warn
https://www.foxnews.com/lifestyle?lid=b49mjn40oukg
Skin Sloughing in an Immunocompromised Elderly Male Rebecca Wang, MD; Christina Pierce, MD; Pavela Bambekova, MD; Sandra Osswald, MD; Robert Gilson, MD (+... +... +...)
Skin Sloughing in an Immunocompromised Elderly Male
Rebecca Wang, MD; Christina Pierce, MD; Pavela Bambekova, MD; Sandra Osswald, MD; Robert Gilson, MD
https://www.medscape.com/viewarticle/skin-sloughing-immunocompromised-elderly-male-2026a10016jt
Cutis: Cutaneous Medicine for the Practitioner
Cutis is a peer-reviewed clinical journal for dermatologists and is referenced in Index Medicus/MEDLINE. Concise clinical articles present the practical side of dermatology and help physicians to improve patient care. Original research, image quizzes, cases and reviews, and columns are written and reviewed by industry leaders.
https://www.medscape.com/cutis
Clinical Review
Second-Intention Healing on the Head and Neck
Second-intention healing may yield favorable cosmetic and functional outcomes for surgical wounds of the head and neck, even in traditionally less favorable locations.
Cutis, November 10, 2026
https://www.medscape.com/index/list_16869_0
Oncology Journal Articles: Increasing Molecular Testing Compliance via Molecular Rounds (+...)
Oncology Journal Articles
Increasing Molecular Testing Compliance via Molecular Rounds
By launching weekly "molecular rounds," a VA oncology program raised lung cancer molecular testing compliance to 78% and prostate cancer to 51%.
Federal Practitioner, September 17, 2026
https://www.medscape.com/index/list_6235_0
Oncology Perspective: Avoid the Arm on the Same Side as Breast Cancer Surgery? (+...)
Oncology Perspective
Avoid the Arm on the Same Side as Breast Cancer Surgery?
Dr Paauw examines evidence for avoiding procedures in the arm on the same side as breast cancer treatment.
Medscape Internal Medicine, November 09, 2026
https://www.medscape.com/index/list_13293_0
Oncology News: Symptom Burden Linked to Less Spending on Cancer Treatment (+...)
Oncology News
Symptom Burden Linked to Less Spending on Cancer Treatment
A higher patient-reported symptom burden is linked to less spending on cancer treatment but more spending on emergency visits, hospital stays, and home care, a study finds.
Medscape Medical News, November 10, 2026
https://www.medscape.com/index/list_13474_0
Symptom Burden Linked to Less Spending on Cancer Treatment Will Pass
https://www.medscape.com/viewarticle/symptom-burden-linked-less-spending-cancer-treatment-2026a10016wm?src=
In people with cancer, a higher patient-reported symptom burden was linked to lower spending on cancer treatment and higher spending on other care.
Among nearly 286,000 patients in their first year after diagnosis, each 10-point increase in symptom score was associated with a 9.4% decrease in cancer-directed costs over the next 30 days, in the large population-based study from Ontario, Canada. Each 10-point increase was also associated with 18.4% higher ancillary costs, such as emergency department visits, hospital stays, and home care, whereas total costs were 4.1% lower.
Lung Cancer Screening Lags Amid Low Awareness and Health Access Tara Haelle
https://www.medscape.com/viewarticle/lung-cancer-screening-lags-amid-low-awareness-and-health-2026a10016o5?ecd=WNL_trdalrt_pos1_ous_261110_etid8886262&uac=148436CN&impID=8886262
PHOENIX — Lung cancer screenings have continued to lag behind other types of cancer screenings, due in part to a communication gap in which few people eligible for screening are discussing their risk with clinicians, according to findings presented at CHEST, the annual meeting of the American College of Chest Physicians, in Phoenix on October 20.
lunes, 9 de noviembre de 2026
Why the latest heart drug failures should make us all more skeptical of AI hype A pioneering new approach was supposed to transform biopharma research. Instead, it flopped
https://www.statnews.com/2026/11/08/heart-drug-failures-lessons-for-artificial-intelligence-from-aha-conference/
By Matthew HerperNov. 8, 2026
Senior Writer, Medicine, Editorial Director of Events
Matthew Herper
matthew.herper@statnews.com
Matthew Herper covers medical innovation — both its promise and its perils.
Ch 1: Overview of C3G and Diagnosis Challenges
Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses complement 3 glomerulopathy (C3G) and its diagnostic challenges.
C3G and the Pediatric VALIANT Study (++)
Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discussed complement 3 glomerulopathy (C3G) with CheckRare.
Complement 3 glomerulopathy (or C3G) is a form of membranoproliferative glomerulonephritis, an inflammatory process. It occurs when the complement system, which is a key part of the body’s defenses to fight off bacterial and viral infection, is continually engaged. When this occurs, plasma complement fragments are deposited in the glomerulus, creating inflammation and disrupting glomerular function. At this point, the clinical features of C3G are apparent, including hematuria and proteinuria.
As it is a rare disorder, it is not regularly taught during medical training, and primary care physicians will not typically see several patients with C3G. Therefore, it will not often be in the forefront of clinician’s mind when confronted with symptoms associated with C3G. Primarily a disease of the young, pediatricians may easily mistake it for other conditions, such as postinfectious (or infection-related) glomerulonephritis, which typically follows a streptococcal infection. The microscopic appearance of biopsy samples from patients with C3G may even look similar to those with postinfectious glomerulonephritis.
The VALIANT trial was a phase 3, double-blind, placebo-controlled study of the efficacy and safety of pegcetacoplan in 124 adolescent and adult patients with either C3G or the related disorder primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The primary endpoint was to determine this complement 3 inhibitor’s effect on proteinuria.
After 26 weeks of treatment, pegcetacoplan was associated with a 68% relative reduction in the urinary protein:creatinine ratio, the indicator of proteinuria, compared with the individuals receiving placebo. The study drug was not associated with a safety profile that was significantly different from that observed in the placebo group. A longer-term extension study demonstrated that the proteinuria reduction is maintained, along with kidney function, through at least 52 weeks. “Improvement in proteinuria really does herald long-term benefit,” stated Dr. Dixon. “The longer we see preservation of GFR, the more confident we are that these drugs will be effective over the long term.”
The VALIANT data support that blocking C3 has dramatic benefits by limiting complement deposition in the glomerulus in both adolescent and adults with C3G. With earlier intervention, long-term damage to kidney function may be prevented.
Dr. Dixon commented that although pegcetacoplan was effective in patients ages 12 years or greater, there is still an urgent need for treatment of younger patients, for which no effective treatment is approved. He added that since we are all born with a fixed number of glomeruli, kidney damage in young patients means their reserve of kidney function later in life will be limited. In his experience, 50% of patients with C3G will experience a halving of their kidney function within 10 years, and will need dialysis and/or a kidney transplant.
C3G and the Pediatric VALIANT Study (Full Program)
De-escalation of Surgery Safe for Low-Risk Thyroid Cancer Nancy A. Melville
https://www.medscape.com/viewarticle/de-escalation-surgery-safe-low-risk-thyroid-cancer-2026a10016ol?src=
PHILADELPHIA — Patients with low-risk differentiated thyroid cancer treated with the less invasive approach of thyroid lobectomy vs total thyroidectomy, as recommended in American Thyroid Association (ATA) de-escalation guidelines from 2015, show no significant increases in the risk for disease recurrence, new research found.
The U.S. Age-Adjusted Death Rate Reached a Record Low in 2025: What Drove the Decline?
https://aspe.hhs.gov/reports/death-rate-record-low
The HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) recently released new analysis examining America’s record-low overall age-adjusted death rate in 2025 and substantial progress in reducing prescription opioid exposure and expanding treatment.
The ASPE report, The U.S. Age-Adjusted Death Rate Reached a Record Low in 2025: What Drove the Decline?, and accompanying analysis, Two Opioid Policy Trends Are Moving in the Right Direction: Sustaining a Decade of Progress, highlight how actions across President Trump’s two terms to reduce unnecessary opioid prescribing, combat illicit fentanyl, and strengthen treatment and recovery have led opioid-related deaths in the United States to plummet to the lowest since President Trump declared a public health emergency in 2017.
In January 2026, President Trump established the Great American Recovery to better align federal programs and integrate prevention, treatment, recovery support, and reentry across systems. HHS Faith Center Director Monty Burks is the Executive Director of the Great American Recovery.
https://www.hhs.gov/press-room/hhs-reports-opioid-deaths-lowest-nearly-decade.html
Fostering and Faith: Partnerships to Serve Families
On Wednesday, December 17th, 2025 the U.S. Department of Health and Human Services Center for Faith held a webinar, 'Fostering and Faith: Partnerships to Serve Families', on how government seeks to partner with faith communities making a difference for foster youth in America.
Living with Alzheimer’s and Dementia
The U.S. Department of Health and Human Services Center for Faith convened a webinar on how faith communities, caregivers, families, and community partners are supporting individuals living with Alzheimer’s disease and other dementias titled, "Living with Alzheimer’s and Dementia: How Faith Communities Can Support Individuals, Caregivers, and Families" on October 28, 2026.
A Community for Every Child: Strengthening Families Together Fecha y hora 18 nov 2026 04:00 p. m.
https://hhsgov.zoomgov.com/webinar/register/WN_RfHA8YqQSiyG6zfB7gxahg#/registration
November is National Adoption Month and the HHS Faith Center will lead a discussion on the community coming together and caring for children and families by building lasting relationships, and providing encouragement and support for the webinar, ‘ A Community for Every Child: Strengthening Families Together’ on November 18th, 2026, at 2:00 PM ET on Zoom.
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition FDA Drug Safety Communication – November 9, 2026
https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential?utm_medium=email&utm_source=govdelivery
What Safety Concern is FDA Announcing?
The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss.
Mirum’s Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study by Chad Birt| Published on: Nov 2, 2026
Mirum’s Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study
by Chad Birt| Published on: Nov 2, 2026
Mirum Pharmaceuticals recently announced positive topline results from its phase 3 EXPAND study, evaluating Livmarli (maralixibat) for cholestatic pruritus in patients six months and older with ultra-rare cholestatic liver diseases. Jennifer Vittorio, MD, an EXPAND investigator, an Associate Professor of Pediatrics, and the Medical Director of Pediatric Liver Transplantation at NYU Langone Health, discusses the findings.
https://checkrare.com/mirums-livmarli-achieves-primary-endpoint-in-phase-3-expand-study/
Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP) by Chad Birt| Published on: Nov 9, 2026
Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP)
by Chad Birt| Published on: Nov 9, 2026
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
https://checkrare.com/garetosmab-demonstrates-sustained-efficacy-in-adults-with-fibrodysplasia-ossificans-progressiva-fop/
Adding Chemotherapy to Pembrolizumab Extends Progression-Free Survival in Lung Cancer With High PD-L1 Expression
https://www.medscape.com/viewarticle/adding-chemotherapy-pembrolizumab-extends-progression-free-2026a100167j?src=
The addition of platinum-based chemotherapy to pembrolizumab extended median progression-free survival (PFS) from 6.9 to 16.1 months in patients with previously untreated advanced non-small cell lung cancer (NSCLC) and PD-L1 expression of 50% or higher in a phase 3 trial. Severe treatment-related adverse events were more frequent with the combination.
FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy (+++)
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy?utm_medium=email&utm_source=govdelivery
2026 Safety and Availability Communications
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications
OTP Guidance Webinar: Potency Assurance for Cellular and Gene Therapy Products
December 10, 2026
Office of Therapeutic Products (OTP)
https://www.fda.gov/vaccines-blood-biologics/office-therapeutic-products-otp-events-meetings-and-workshops/otp-guidance-webinar-potency-assurance-cellular-and-gene-therapy-products-12102026?utm_medium=email&utm_source=govdelivery
domingo, 8 de noviembre de 2026
Medical Device Cybersecurity
https://www.fda.gov/medical-devices/medical-device-cybersecurity?utm_medium=email&utm_source=govdelivery
FDA Enhances Medical Device Cybersecurity Web Content
The U.S. Food and Drug Administration has updated its medical device cybersecurity webpages to make key information and resources easier to find and use.
What’s new:
Refreshed main page within the Medical Devices section, with improved visibility and usability.
Updated Guidance and FAQs with current information.
Two new webpages with resources on securing medical devices and information about cybersecurity collaborations.
Explore the updated content to find resources and information to help address cybersecurity considerations for medical devices.
Brown fat may benefit cardiovascular, psychiatric health
https://www.nih.gov/news-events/nih-research-matters/brown-fat-may-benefit-cardiovascular-psychiatric-health
Brown fat may benefit cardiovascular, psychiatric health
At a Glance
Researchers found brown fat activity was linked to lower odds of cardiometabolic and psychiatric diseases.
A blood pressure medication boosted brown fat activity in mice, which suggests existing drugs could be repurposed to activate brown fat.
3D illustration of brown fat cell.
Brown fat cells contain many mitochondria (light-brown elongated ovals), which burn energy to create heat.
Love Employee / Shutterstock
Brown fat burns energy to produce heat. This is different from white fat, which stores energy in the body. Brown fat reserves are found deep in the neck, thorax, armpits, and along the spine. The amount of brown fat in humans varies by factors such as age, sex, and body-mass index.
Senescence-targeting nanoparticles may enhance immunotherapy
https://www.nih.gov/news-events/nih-research-matters/senescence-targeting-nanoparticles-may-enhance-immunotherapy
Senescence-targeting nanoparticles may enhance immunotherapy
At a Glance
Researchers developed a nanoparticle treatment in mice to eliminate certain cells that can drive tissue scarring around tumors and prevent anti-tumor therapies from working.
The approach made tumors more sensitive to therapies that boost the immune response to cancer and might one day be applied to humans.
The nanoparticle treatment could help immunotherapy work better on lung cancer (red) growing in areas of fibrosis (green).
NIH’s National Cancer Institute / Fox Chase Cancer Center
Chronic inflammation can fuel a form of scarring called fibrosis linked to cancer. Areas of fibrotic tissues often contain lots of damaged cells that no longer divide nor die off when they should. These “senescent” cells drive inflammation and fibrosis, and they inhibit nearby immune cells. As a result, tumors surrounded by fibrosis are harder to treat with immunotherapies that spur the immune system to attack cancer.
Stroke recovery tracked with wearable device
Stroke recovery tracked with wearable device
At a Glance
A wearable device tracked how patients recovered the ability to use their arms after a stroke.
The digital tool could help personalize treatment and make it easier to test new treatments.
Wrist-worn devices can provide useful information about people’s ability to use their arms during stroke rehab.
voronaman / Shutterstock
After a stroke, people may have trouble moving their arms. Trained specialists use clinical tests to track whether physical therapy is helping a patient recover that ability. However, those tests are time-consuming and often cannot detect small changes in how people move. They also don’t capture how people use their arms in everyday life.
https://www.nih.gov/news-events/nih-research-matters/stroke-recovery-tracked-wearable-device
FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy. HNSCC is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies.
Rybrevant Faspro is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma that is associated with human papillomavirus (HPV).
Approval was based on trial results showing that more than double the percentage of patients responded to the drug compared to currently approved therapies. This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy.
“Today’s approval represents a meaningful step forward for patients with head and neck squamous cell carcinoma, a disease where treatment options have historically been limited and outcomes remain poor,” said Angelo De Claro, M.D., director of the FDA’s Oncology Center of Excellence. “This therapy offers patients and their physicians a new option with the potential to make a real difference in people’s lives.”
Shorter-Course Radiotherapy Is Safe Option for High-Risk Breast Cancer Dawn Attride
https://www.medscape.com/viewarticle/shorter-course-radiotherapy-safe-option-high-risk-breast-2026a10010pm?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665
Locoregional recurrence remained low over 10 years in patients with high-risk breast cancer who received shorter courses of radiotherapy after mastectomy in a phase 3 trial.
Among postmastectomy patients requiring regional nodal irradiation, hypofractionated radiotherapy and conventional fractionated radiotherapy showed comparable cumulative incidence of locoregional recurrence at 5 years (9.6% vs 8.6%), the primary endpoint of the trial. There were no significant differences in survival outcomes or increases in severe late adverse effects.
PI3K Inhibitors in 2026: How a Class Built on Withdrawn Approvals Is Producing Its Strongest Breast Cancer Data Yet
https://www.medscape.com/c99/p10/pi3k-inhibitors-2026-how-class-built-withdrawn-approvals-2026a1000z8a?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665
Two PI3K inhibitors no longer exist in the United States, and two more survive only with indications stripped away. Copanlisib lost its approval in March 2024 after a required confirmatory trial failed to verify the progression-free survival benefit that had earned it accelerated approval in follicular lymphoma.FDA Umbralisib was pulled from the market entirely in June 2022 after updated trial data showed a possible increased risk of death.FDA Duvelisib's follicular lymphoma indication was voluntarily withdrawn in December 2021, and in July 2024 its label gained a new boxed warning for treatment-related mortality with an explicit instruction against first- or second-line use. Copiktra PI Idelalisib's follicular and small lymphocytic lymphoma indications were withdrawn in January 2022, leaving only a chronic lymphocytic leukemia indication on its label.
Novel ADC Extends PFS in HER2-Low Breast Cancer
https://www.medscape.com/viewarticle/novel-adc-extends-pfs-her2-low-breast-cancer-2026a100146i?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665
The HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan more than doubled progression-free survival compared with standard chemotherapy in patients with HER2-low advanced breast cancer in the phase 3 HORIZON-Breast06 trial.
sábado, 7 de noviembre de 2026
3D Printed Treatment Options | The CheckRare Brief by CheckRare Staff| Published on: Nov 4, 2026
3D Printed Treatment Options | The CheckRare Brief
by CheckRare Staff| Published on: Nov 4, 2026
In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.
https://checkrare.com/3d-printed-treatment-options-the-checkrare-brief/
A Family’s Journey with Prader-Willi Syndrome by Chad Birt| Published on: Nov 5, 2026
A Family’s Journey with Prader-Willi Syndrome
by Chad Birt| Published on: Nov 5, 2026
Maria Picone, co-founder and CEO of the TREND Community, and mother of a 14-year-old with Prader-Willi syndrome (PWS), discusses her family’s journey with PWS, including why more research and better data are so important.
https://checkrare.com/a-familys-journey-with-prader-willi-syndrome/
C3G and the Pediatric VALIANT Study Bradley Dixon, MD
https://checkrare.com/c3g-and-the-pediatric-valiant-study/
C3G and the Pediatric VALIANT Study
Bradley Dixon, MD
Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses complement 3 glomerulopathy (C3G) and the pediatric VALIANT study.
Climate change and health: 10 years on, what next? The Lancet (+...)
Climate change and health: 10 years on, what next?
The Lancet
https://www.thelancet.com/journals/lancet/issue/vol408no10567/PIIS0140-6736(26)X2042-6
The Paris Agreement came into force in 2016, a watershed in collective international action on climate change. That year also saw the creation of the Lancet Countdown on health and climate change, established to track the health effects of climate change and climate action. The past 10 years may have brought disheartening setbacks in climate policy, but there have also been huge advances in the understanding of and attitudes towards climate change.
Health has become a key aspect of climate policy. COP28 had the first official Health Day, elevating health in climate negotiations, and climate laws referencing health rose sharply after 2016. The Countdown has helped to drive that change, growing into a network of regional centres across Africa, Asia, Europe, Latin America, Oceania, and Small Island Developing States that produces locally relevant indicators and evidence that have shaped policy and held governments to account. Advances in science have better illuminated the relationships between climate and health, including the adverse impacts of heat, drought, extreme rainfall, and infectious diseases such as dengue and cholera.
Amyloid fibrils help deliver RNA into sperm and embryos Often associated with neurodegenerative disease, amyloid fibrils may also help transport genetic material during fertilization. Written byBree Foster, PhD
Amyloid fibrils help deliver RNA into sperm and embryos
Often associated with neurodegenerative disease, amyloid fibrils may also help transport genetic material during fertilization.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/amyloid-fibrils-help-deliver-rna-into-sperm-and-embryos-17629
Amyloid fibrils — protein structures commonly associated with neurodegenerative diseases such as Alzheimer's and Parkinson's — may have an unexpected role in reproduction, according to a study recently published in Molecular Cell.
Researchers at Columbia University's Zuckerman Institute found that amyloid fibrils in seminal fluid can bind RNA and help transport it into sperm and embryos. The findings suggest these structures may have a previously unrecognized role in transferring genetic material during fertilization, while also raising questions about whether their properties could eventually be harnessed to deliver RNA-based therapeutics or components of gene-editing technologies such as CRISPR.
New wave of health and STEM candidates could reshape US science policy A massive cancer drug deal, a new license for gut-targeted drugs, and both regulatory and company-led halts on clinical trials led the news this week. Brought to you byDDN editorial team
New wave of health and STEM candidates could reshape US science policy
A massive cancer drug deal, a new license for gut-targeted drugs, and both regulatory and company-led halts on clinical trials led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/new-wave-of-health-and-stem-candidates-could-reshape-us-science-policy-17640
The election of a new wave of candidates with backgrounds in medicine, science, and engineering could have implications for US health and science policy as the country grapples with healthcare costs, research funding, and disputes over vaccines and public health. The victories included Dr Amy Acton, Ohio’s former health director who was elected governor of Ohio, Dr Abdul El-Sayed, a public health administrator who won a US Senate seat in Michigan, and Dr Jasmine Clark, a microbiologist and molecular geneticist who was elected as Congress woman of the state of Georgia. STEM professionals remain relatively rare in elected office — fewer than 10 percent of members of Congress have backgrounds in medicine, public health, or engineering — potentially giving the incoming lawmakers greater influence and expertise over debates on healthcare access, federal research funding, and public health policy at a time of major changes to the US scientific and public health infrastructure. – Bree Foster
RARE Round-up - keeping you up-to-date (+...)
Aicardi syndrome is incredibly rare and mostly affects girls; it is not known what causes it, however, a research team led by Dr Igna Van den Veyver at Baylor College of Medicine, Texas, has dedicated more than 30 years trying to find out and the quest continue
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=a879f992-d7b6-4577-a1e2-3ba26643b60c&pnum=67
Popular drinks linked to heart attacks, cardiac arrest in young adults, study finds By Melissa Rudy Fox News Published November 7, 2026 8:00am EST (+ +... +...)
https://www.foxnews.com/health/popular-drinks-linked-heart-attacks-cardiac-arrest-young-adults-study-finds
Popular drinks linked to heart attacks, cardiac arrest in young adults, study finds
About 45% of cardiovascular events linked to stimulant products involved adults ages 18 to 34
Melissa Rudy By Melissa Rudy Fox News
Published November 7, 2026 8:00am EST
Americans who 'screw up' their eating should use a simple fix, says Stanford scientist
https://www.foxnews.com/lifestyle?lid=b8pdi58so9ng
Fitness influencer's vacation getaway takes scary turn after headache leads to ICU
https://www.foxnews.com/health
Trends, ethnic inequalities, and determinants of multiple nutrition-related health outcomes among Chinese children and adolescents aged 7–18 years: evidence from four national school health surveys, 2005–19 Xinli Song, PhDa,b,* ∙ Shan Cai, PhDa,b,* ∙ Prof Sarah Baird, PhDd ∙ Yi Zhang, PhDa,b ∙ Ruolin Wang, PhDa,b ∙ Jianuo Jiang, PhDa,b ∙ et al. /++...+)
Trends, ethnic inequalities, and determinants of multiple nutrition-related health outcomes among Chinese children and adolescents aged 7–18 years: evidence from four national school health surveys, 2005–19
Xinli Song, PhDa,b,* ∙ Shan Cai, PhDa,b,* ∙ Prof Sarah Baird, PhDd ∙ Yi Zhang, PhDa,b ∙ Ruolin Wang, PhDa,b ∙ Jianuo Jiang, PhDa,b ∙ et al.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00192-1/fulltext?dgcid=hubspot_email_conferencealerts_cams26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9IRv2t72SxW6FQIvaAKE_mfk_ecx5GZfMM_IBRY_PJmkf_Asx0COZ15TVMDkLontSELvWmtY0_iDuCsqEboIfSoXV_ow&_hsmi=100253755915&utm_source=hs_email
Online First
Below are the latest The Lancet Public Health articles published ahead of the monthly online issue
https://www.thelancet.com/journals/lanpub/onlinefirst
Prevalence and spectrum of skin diseases in adults in China: a nationwide cross-sectional study
Jing Li, PhD*,a ∙ Hui Jin, MDa,b,* ∙ Ying Zhang, MSa,b,d,* ∙ Peimei Zhou, MDe,* ∙ Yaoda Hu, PhDf,* ∙ Lianhua Zhang, BSg ∙ et al.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00126-X/fulltext?dgcid=hubspot_email_conferencealerts_cams26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-__l5HaXtI5Xsqk3vX4BB9WqpfbiNux7JgeFdLVxMjUIypc_Fwdsj-woLbsBKaTSrkTmPJqU_NEwWZ51Geg674RBLj7zQ&_hsmi=100253755915&utm_source=hs_email
Suscribirse a:
Entradas (Atom)
.png)
